This is the protocol for a review and there is no abstract. The objectives are as follows:, To determine the effects of second generation dihydropyridine calcium channel blockers in patients with moderate to advanced heart failure (New York Heart Association class II - IV). Patient groups treated with second generation dihydropyridine calcium channel blockers in addition to standard medication (digoxin, ACE-inhibitors, beta-blockers or diuretics) are compared with patients on placebo in addition to standard medication on main outcome measures mortality, morbidity, hospital (re-) admissions and cardiac events. Patient groups are also compared on the secondary outcome measures haemodynamic effect and quality of life